Northland Securities Thinks Intrexon’s Stock is Going to Recover

By Austin Angelo

Northland Securities analyst Robert Breza reiterated a Buy rating on Intrexon (NYSE: XON) yesterday and set a price target of $21. The company’s shares closed yesterday at $11.81, close to its 52-week low of $11.80.

According to TipRanks.com, Breza is a 3-star analyst with an average return of 2.6% and a 52.3% success rate. Breza covers the Technology sector, focusing on stocks such as Barracuda Networks, Coupa Software Inc, and CommVault Systems.

Intrexon has an analyst consensus of Moderate Buy, with a price target consensus of $21.

Based on Intrexon’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $54.43 million and GAAP net loss of $18.66 million. In comparison, last year the company earned revenue of $48.99 million and had a GAAP net loss of $28.98 million.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XON in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intrexon Corp. operates as a biotechnology company. The company engages in the field of synthetic biology, which is an emerging discipline that applies engineering principles to biological systems.